Nonfunctioning pituitary macroadenomas (1 cm or larger) tend to be more aggressive than functioning pituitary adenomas. They frequently present with mass effect symptoms, including headache, visual field compromise, cranial nerve palsies affecting extraocular muscles, and pituitary apoplexy. Larger macroadenomas frequently cause some hypopituitarism, particularly hypogonadotropic hypogonadism. Nonfunctioning pituitary microadenomas are asymptomatic.
1. Pituitary hormone hypersecretion
All patients with a pituitary adenoma require testing for pituitary hormone hypersecretion. A serum PRL is obtained to screen for prolactin hypersecretion; women with hyperprolactinemia are tested for pregnancy with a serum hCG. Clinical suspicion should dictate whether to formally test for Cushing disease or acromegaly.
2. Anterior hypopituitarism
Men should have following tests: serum free T4, TSH, morning serum testosterone and free testosterone. Serum LH and FSH should be obtained in men with low serum testosterone, women who are postmenopausal, and younger women with amenorrhea. Serum sodium and glucose should also be obtained in all patients. A serum IGF-1 is drawn to screen for GH deficiency. Younger patients with short stature who have not fused their epiphyses should have a full evaluation for growth hormone deficiency.
3. Pituitary macroadenomas
Patients with a macroadenoma that impinges upon the optic chiasm require formal visual field testing. A cosyntropin stimulation test is performed for patients with hyponatremia or symptoms of possible hypoadrenalism.
Pituitary dynamic contrast-enhanced MRI (3T) is the imaging modality of choice for the evaluation and follow-up of pituitary adenomas. About 10% of nonfunctioning pituitary microadenomas enlarge over several years, whereas 23% of pituitary nonfunctioning macroadenomas enlarge significantly. Nonfunctioning pituitary microadenomas that are smaller than 5 mm require no further MRI follow-up. For nonfunctioning pituitary adenomas 5 mm or larger, repeat MRI is recommended at 6 months, then yearly for 3 years. If no enlargement is noted, MRI surveillance can then be done less frequently.